title: Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel.
abstract: The incidence of cytogenetic abnormalities in childhood de novo acute myeloid leukaemia (AML) and its prognostic significance was assessed in an Israeli paediatric referral centre. Cytogenetic analysis was successful in 86 of 97 children (< 20 years of age) diagnosed between 1988 and 2002 with de novo AML. Fluorescence in situ hybridization analysis detected new information in 11 of them, leading to reassignment in cytogenetic group classification. The incidence of the various cytogenetic subgroups was as follows: normal - 9%; t(11q23) - 22%; t(8;21) - 13%; t(15;17) - 8%; inv(16) - 3.4%; abn(3q) - 4.6%; 7/7q-(sole or main) - 5.8%; del(9q)(sole) and +21(sole) - 4.6% each; t(8;16) - 2.3%; t(6;9), t(1;22), +8(sole) - 1.1% each; and miscellaneous - 18%. The overall survival (OS) and event-free survival (EFS) (4 years) for 94 patients treated with the modified Berlin-Frankfürt-Münster (BFM) AML protocols (non-irradiated) were 59.9% (SE = 5%) and 55.7% (SE = 5%), respectively, and for the favourable t(8;21), t(15;17) and inv(16), OS was 60% (SE = 15%), 83% (SE = 15%) and 100% respectively. For the normal group it was 62% (SE = 17%), miscellaneous 64% (SE = 12%), t(11q23) 44.6% (SE = 11%) and of the -7/7q-, del(9q)(sole) or t(6;9), none had survived at 4 years. The incidence of cytogenetic subgroups in the Israeli childhood AML population and their outcome were similar to other recently reported paediatric series. Cytogenetic abnormalities still carry clinical relevance for treatment stratification in the context of modern chemotherapy.
authors.affiliation: Centre of Pediatric Hematology/Oncology, Schneider Children's Medical Centre of Israel, Petah Tiqva, Israel. bstark@clalit.orgil
authors.forename: Batia
authors.initials: B
authors.lastname: Stark
authors.forename: Marta
authors.initials: M
authors.lastname: Jeison
authors.forename: Leticia Glazer
authors.initials: LG
authors.lastname: Gabay
authors.forename: Jacques
authors.initials: J
authors.lastname: Mardoukh
authors.forename: Drorit
authors.initials: D
authors.lastname: Luria
authors.forename: Irit
authors.initials: I
authors.lastname: Bar-Am
authors.forename: Gali
authors.initials: G
authors.lastname: Avrahami
authors.forename: Yossef
authors.initials: Y
authors.lastname: Kapeliushnik
authors.forename: Dalia
authors.initials: D
authors.lastname: Sthoeger
authors.forename: Gavriel
authors.initials: G
authors.lastname: Herzel
authors.forename: David M
authors.initials: DM
authors.lastname: Steinberg
authors.forename: Ian J
authors.initials: IJ
authors.lastname: Cohen
authors.forename: Yacov
authors.initials: Y
authors.lastname: Goshen
authors.forename: Jerry
authors.initials: J
authors.lastname: Stein
authors.forename: Rina
authors.initials: R
authors.lastname: Zaizov
authors.forename: Isaac
authors.initials: I
authors.lastname: Yaniv
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D025063:Chromosome Disorders / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D002985:Clinical Protocols; D020732:Cytogenetic Analysis; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D007231:Infant, Newborn; D007557:Israel; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008677:Metaphase; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome